REPLIGEN CORP Operating Lease, Right-of-Use Asset, Amortization Expense
REPLIGEN CORP (RGEN) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $9.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-07-29
- REPLIGEN CORP operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $4.71M, a 0.55% increase year-over-year.
- REPLIGEN CORP operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $4.78M, a 6.49% increase year-over-year.
- REPLIGEN CORP operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $4.64M, a 12.10% increase year-over-year.
- REPLIGEN CORP operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $4.40M.
- REPLIGEN CORP operating lease, right-of-use asset, amortization expense for fiscal 2025 was $18.21M, a 7.83% increase from fiscal 2024.
- REPLIGEN CORP operating lease, right-of-use asset, amortization expense for fiscal 2024 was $16.89M, a 3.81% decline from fiscal 2023.
- REPLIGEN CORP operating lease, right-of-use asset, amortization expense for fiscal 2023 was $17.56M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $9.49M 10-Q · filed 2026-07-29 | $14.13M derived: sum of 3 quarters · filed 2026-07-29 | $18.53M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $4.78M 10-Q · filed 2026-05-06 | $9.42M derived: sum of 2 quarters · filed 2026-05-06 | $13.82M derived: sum of 3 quarters · filed 2026-05-06 | $18.50M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $4.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.04M derived: sum of 2 quarters · filed 2026-02-26 | $13.73M derived: sum of 3 quarters · filed 2026-07-29 | $18.21M 10-K · filed 2026-02-26 |
| 2025-09-30 | $4.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $9.09M derived: sum of 2 quarters · filed 2026-07-29 | $13.57M 10-Q · filed 2025-11-04 | $17.71M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $4.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $9.17M 10-Q · filed 2026-07-29 | $13.31M derived: sum of 3 quarters · filed 2026-07-29 | |
| 2025-03-31 | $4.48M 10-Q · filed 2026-05-06 | $8.62M derived: sum of 2 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $4.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $16.89M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $12.75M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $17.56M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |